New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
But Perspective sinks again.
